The P-III (AEGEAN) trial evaluates the safety & tolerability of Imfinzi + neoadjucant CT vs CT alone in patients with NSCLC
The results from the combination therapy demonstrated a statistically significant improvement in pCR & MPR, consistent safety & tolerability, without a decrease in the number of patients to be able to undergo successful surgery vs CT alone
The company is evaluating Imfinzi in other ongoing trials for the treatment of early stages of lung cancer incl. NSCLC (ADJUVANT BR.31), unresectable NSCLC (PACIFIC-2/4/5/8/9) & limited-stage SCLC (ADRIATIC). Imfinzi has also been approved in the US, Japan, China, the EU & other countries for the treatment of unresectable stage III NSCLC based P-III (PACIFIC) trial & extensive-stage SCLC based on the P-III (CASPIAN) trial
Ref: AstraZeneca | Image: AstraZeneca
